Camurus Advances CAM2029 Review for Acromegaly with FDA's Acceptance of Resubmission

In an encouraging development for patients suffering from acromegaly, Camurus (NASDAQ: CAMX) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of the New Drug Application (NDA) for CAM2029. This innovative treatment, which is an octreotide extended-release injection, has raised anticipation for its potential to improve the lives of those afflicted with this rare disorder.

The FDA has set a target action date of December 18, 2026, under the Prescription Drug User Fee Act (PDUFA). This resubmission comes after a Complete Response Letter (CRL) issued on June 10, 2026, which raised no concerns regarding the efficacy or safety of CAM2029. Instead, the CRL pointed to issues stemming from a Good Manufacturing Practice (cGMP) inspection at a third-party manufacturer. Camurus has confirmed that the contract manufacturer has effectively implemented all necessary remediation actions and is prepared for inspection, paving the way for the review process to advance.

Fredrik Tiberg, President and CEO of Camurus, expressed optimism about the collaboration with the FDA, stating, "We look forward to continuing our efforts to make CAM2029 available to patients with acromegaly in the United States." This commitment demonstrates the organization's dedication to bringing this treatment to market and addressing the ongoing needs of patients.

What is CAM2029?

CAM2029 is a subcutaneously administered long-acting octreotide depot that leverages the proprietary FluidCrystal® technology developed by Camurus for convenient, once-monthly self-administration via an autoinjector pen. This method not only simplifies patient compliance but also enhances the therapeutic experience by reducing the frequency of injections. The NDA submission is backed by data from a robust clinical program, including seven studies—two of which were pivotal Phase 3 trials within the ACROINNOVA program.

Background on Acromegaly

Acromegaly is a progressive endocrine disorder often caused by a pituitary tumor that secretes excess growth hormone, leading to increased levels of insulin-like growth factor 1 (IGF-1). This condition results in abnormal growth of bones and tissues, which can culminate in enlarged body parts, including hands, feet, and facial features, in addition to causing various symptoms such as fatigue, joint pain, headaches, excessive sweating, and visual disturbances. Given the potential for serious complications, including impaired quality of life and increased mortality rates, effective treatment options are crucial. Current estimates suggest that around 60 cases of acromegaly exist per million people, highlighting the need for more accessible therapies.

Global Perspective and Future Potential

In addition to the review process in the United States, CAM2029 has already received marketing authorization in both the European Union and the United Kingdom under the brand name Oczyesa®. Furthermore, applications for marketing authorization are currently under review in two other countries, indicating a strong international interest in this innovative formulation.

The clinical efficacy of CAM2029 has shown promising outcomes. It has demonstrated a significant increase in bioavailability compared to traditional long-acting octreotide therapies and has proven effective in controlling biochemical and symptomatic responses in patients. The results of the ACROINNOVA program exhibit not only superior control of the disease compared to placebo but also improvements in patient quality of life metrics and treatment satisfaction.

At Camurus, the commitment extends beyond just acromegaly treatment. The NDA indicates a pathway to explore the efficacy of CAM2029 in treating other conditions, including gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). The continuing R&D advances at Camurus aim to provide patients with groundbreaking, effective treatments for serious conditions.

As Camurus navigates the NDA resubmission process with the FDA, stakeholders will certainly keep a keen eye on developments leading up to the target action date. Anticipation among the medical community and patients alike builds as the possibilities surrounding CAM2029 unfold further, offering renewed hope to those affected by acromegaly.